The new anti-amyloid drugs for AD are interesting, but an efficacy of 3 points on a 144 scale (2%) does not sound so impressive. We also need to understand ARIA much more
Læs også
@Palm_DK @GianniRivera69 Helt sikkert, det har haft kæmpe betydning. Der er jo ingen der kan vide med sikkerhed om den
- Andreas Andersen
- 25. juli 2021
- 0
@Palm_DK @GianniRivera69 Helt sikkert, det har haft kæmpe betydning. Der er jo ingen der kan vide med sikkerhed om den slags beslutninger vil være en […]
@axholm @FrederikMnster @Camilla_Rathcke @SSTSundhed @laegeforeningen Hvad er din pointe med det? En ny sammenligning af de vacciner og så VITT
- Andreas Andersen
- 13. maj 2021
- 0
@axholm @FrederikMnster @Camilla_Rathcke @SSTSundhed @laegeforeningen Hvad er din pointe med det? En ny sammenligning af de vacciner og så VITT risikoen ved nogle COVID-19 vacciner?
Det er dårlig ledelse af Mette Frederiksen, ikke at hjemsende Barbara Berthelsen efter den massive kritik i Minkrapporten. Det handler
- Andreas Andersen
- 11. august 2022
- 0
Det er dårlig ledelse af Mette Frederiksen, ikke at hjemsende Barbara Berthelsen efter den massive kritik i Minkrapporten. Det handler ikke kun om Mette Frederiksens […]
Agree that we need to characterize ARIA better and make sure doctors know how to predict it and manage it. On the efficacy, I struggle to see why such a change ( which is measurable and consistent on a clinical scale which is not so sensitive to begin with) should be meaningless.
If the clinical scale is so bad, then it might not be the best ending point to show efficacy of the drug, that can balance the side effects, expensive price and changes in diagnostic setup of AD. Think further and longer studies will be needed to demonstrate sufficient efficacy that will make a meaningful difference for the patients. Think further and longer studies will be needed to demonstrate sufficient efficacy that will make a meaningful difference for the patients and relatives.